Smart delivery chassis
Develop engineered bacteria as 'living medicines' to deliver vacination agents
Major lack of oral vacines for on-going and new viral infections
Desperate need for widely and easily accessible vaccines
Collaboration with top universities
Seven key features
be taken orally as a pill
survive the acidic environment of the stomach
induce a highly effective combination of systemic and mucosal immunity
an indefinite shelf life without need for cooled transportation and storage
a low production costs with a bioreactor
an high adaptability to a wide range of vaccine agents
an unprecedented biocontainment mechanism (cells will self-destruct once shed in the environment) and stable chromosomal genetic constructs (no plasmids).
Our disruptive solution: modular spore chassis
Our solution employs forefront synthetic biology techniques to genetically engineer anaerobic, spore-forming bacteria (Clostridium Sporogenes) with CRISPR-Cas9 gene editing and allelic exchange technology.
These plasmid and antibiotic-free spores become delivery vehicles that secret antigens with or without adjuvant..
Currently, the state-of-the-art delivery system for many vaccines relies on parenteral administration via needle injections.
Parenteral vaccination very poorly induces mucosal immunity, yet the mucosa is the site of entry for most pathogens.
An oral vaccination platform based on a Clostridium vector would represent a new gold standard for preventive medicine in terms of efficacy, safety, accessibility and ease-of-administration.
Our method has several features
1) Clostridium spores are better equipped for the acidic environment of the stomach.
2) High affinity ligands to M- and dendritic cells increase efficacy. We are eliciting effective systemic and mucosal immune responses.
3) Stable chromosomal integration instead of plasmids prevents horizontal gene transfer.
4) Two-fold biocontainment (temperature kill-switch and anaerobic conditioning) instead of passive biocontainment (single nutrient auxotrophy) guarantees safety.
LivingMed Biotech is a belgian based start-up company, operating at the intersection of microbiology, engineering and immunology. As a spin-off from Maastricht University, taking advantage of more than 100 years combined experience, we have developed a proprietary engineered commensal bacteria as “living medicines” with a first focus on oral vaccination for prevention of infectious diseases in particular Influenza and COVID19.
- LivingBiotech is based at the
“Chanmurly” incubator in Liège
Clos Chanmurly, 13
4000 Liège. Belgium
This is an incubator-facility building close to thecentral station of Liège. We are just 2 minutes away from the highway and easily reachable by public transportation (train/bus).